UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jul 20, 2020
- Strategic partnership with Royalty Pharma plc. enables PTC to strengthen and advance its diversified rare disorders portfolio -   - Conference call scheduled for 8:30 am ET - SOUTH PLAINFIELD, N.J. , July 20, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Jul 08, 2020
- First in human trial for PTC857, the second compound in the Bio-e platform to enter clinical trials - SOUTH PLAINFIELD, N.J. , July 8, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the first subject in the Phase 1 clinical trial evaluating PTC857 in healthy
Additional Formats
Jun 29, 2020
- EU label update supports Translarna use in patients who became non-ambulatory while on therapy - SOUTH PLAINFIELD, N.J. , June 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Additional Formats
Jun 17, 2020
- Oral treatment with novel dual-mechanism of action has the potential to address the two critical elements of COVID-19; viral replication and uncontrolled inflammatory response -   - Randomized, double-blind, placebo-controlled, multi-national Phase 2/3 clinical study with two stages to initiate
Additional Formats
Jun 12, 2020
SOUTH PLAINFIELD, N.J. , June 12, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 10, 2020 it approved non-statutory stock options to purchase an aggregate of 54,675 shares of its common stock and 3,940 restricted stock units ("RSUs"), each representing the
Additional Formats
Jun 12, 2020
- Risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with type 2 or 3 SMA in SUNFISH Part 1 -   - Preliminary 12-month data in the JEWELFISH study in previously treated patients demonstrated increases in SMN protein levels -   - Data presented at
Additional Formats
Jun 10, 2020
- A one-year internship program for recent graduates that will provide work experience and training -   - Internships in all departments from research through commercialization -   - B.S., M.S., Pharm.D., MBA, Ph.D., M.D., and J.D. graduates are all welcome to apply - SOUTH PLAINFIELD, N.J.
Additional Formats
Jun 01, 2020
SOUTH PLAINFIELD, N.J. , June 1, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has successfully completed the acquisition of Censa Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage
Additional Formats
May 28, 2020
SOUTH PLAINFIELD, N.J. , May 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5
Additional Formats
May 27, 2020
SOUTH PLAINFIELD, N.J. , May 27, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the
Additional Formats